ACTRN12609000708257终止2 期
A Randomized Open Label Study Comparing the Efficacy, Safety and Tolerability of Oral Administration of Amantadine and Ribavirin and Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 1 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Immunocompromised as defined by one of either: recent solid organ or hematopoietic cell transplantation, chronic Graft Versus Host Disease (GVHD) requiring systemic immunosuppression, taking at least 2 immunosuppressants, undergoing chemotherapy, taking high dose corticosteroids or Human Immunodeficiency Virus (HIV) positive.
- •Clinical diagnosis of Influenza A infection (mild.moderate or severe)
- •Onset of illness no more than 3 days prior to study entry.
- •Subjects (Male and Female) agree to use contraception through 24 weeks after last dose.
排除标准
- •Use of more than 2 doses of antiviral influenza medications since onset of symptoms
- •Critically ill
- •Creatinine Clearance less than 30 mL/min
- •Known genetic hemoglobinopathy
- •Presence of suspected or diagnosed non influenza infection requiring treatment.
- •Pschyatric or cognitive illness or recreational drug/alcohol use that would affect patient safety and compliance.
- •Documented non-influenza viral infection, including respiratory syncytial virus or Influenza B
- •Women who are pregnant, who are attempting to become pregnant, or who are breast-feeding.
研究者
相似试验
撤回
2 期
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin with Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjectsflu1002146010047438influenzaNL-OMON32856PRA International EDS56
进行中（未招募）
不适用
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin with Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects - TCAD Therapy for treatment of influenza A in immunocompromised subjectsInfluenza A VirusEUCTR2009-015850-39-NLAdamas Pharmaceuticals, Inc250
尚未招募
3 期
Comparing Leflunomide, sulfasalazine and tofacitinib in rheumatoid arthritis patients with methotrexate inadequate responseCTRI/2023/07/055919Indian Rheumatology Association
尚未招募
不适用
Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral ResistanceKCT0003813Yonsei University Health System, Severance Hospital210
进行中（未招募）
1 期
Randomized not blinded clinical trial to compare two sequences oftreatment: STZ-5FU followed by everolimus or everolimus followed by STZ-5FU upon progression in advanced progressive pancreatic neuroendocrinetumors (SEQTOR study)advanced progressive pNETsMedDRA version: 17.1Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-FRGrupo Español de Tumores Neuroendocrinos (GETNE)180